Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ Outlines COVID-19 Plans With Strong Q2 Update

UK Pharma Is Advancing Two MAbs Into COVID-19 Trials

Executive Summary

AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.

You may also be interested in...



AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus

AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine. 

Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Oxford’s long-awaited early stage study produces solid safety and efficacy results, but lags Pfizer/BioNTech and Moderna’s mRNA candidates for antibody response.

AstraZeneca Will Test More Assets Against COVID-19

AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel